QoL is often not assessed in real-world studies; hence, there is limited understanding about the real-world QoL of patients diagnosed with CLL. Besides, studies evaluating QoL have largely focused on comparing treated and untreated populations. In particular, QoL of patients treated with acalabrutinib has not been evaluated in a real-life setting.
The aim of this study is to describe the QoL of CLL patients treated with acalabrutinib between the treatment initiation and twelve months after, in a real-life setting.
Patient enrolled in the PLATON database
Patient ≥18 years old
Treatment naïve CLL patient treated with acalabrutinib in a real life setting. Treatment pattern is Acala mono or Acala + Obinutuzumab
Patient who do not object to his health data collected in PLATON study being re-use for analysis/research purpose
Pregnant women
Patients under protection of justice
Patients over the age of 18 and unable to express their non-opposition
Patients with prior CLL treatments
AstraZeneca
Lead sponsor
Hospitalidee
Collaborator
Hospitalidee has been asserted to be a valid organization name by UHToulouse
Collaborator